Business Context and Reporting Period
This Form 8-K was filed by Oncocyte Corporation (trading symbol: OCX) on July 28, 2022. The report details executive compensation arrangements and modifications to performance goals for senior officers, effective August 2022. The filing does not contain financial results for a specific reporting period but focuses on Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data disclosed relates to executive compensation packages:
- Anish John (SVP Finance/Interim CFO): Annual salary of $330,000; target bonus of 50% of base salary; up to $25,000 in relocation expenses.
- Gisela Paulsen (COO): Annual salary of $415,000; target bonus of 60% of base salary.
- Equity Grants: Significant stock options and restricted stock units (RSUs) were awarded to the CFO, COO, and CSO (Douglas Ross).
Material Changes
The primary material change is the adoption of new compensation programs and the modification of existing performance goals:
- CEO Bonus Modification: The performance objective for CEO Ronald Andrews' 2022 annual bonus was changed from an expense-related objective (actual expenses not exceeding budgeted expenses) to a cash-related objective.
- New Executive Appointments/Compensation: Formalized compensation for the Interim CFO, COO, and CSO, including specific salary increases and equity grants effective August 2022.
Guidance, Outlook, and Risks
Management Commentary and Equity Vesting:
- Time-Based Grants: The Interim CFO received 100,000 stock options vesting over four years (25% after one year, remainder monthly). The COO received 175,000 RSUs vesting 100% on August 15, 2023.
- Performance-Based Grants: The CFO, COO, and CSO each received additional RSUs (150,000, 350,000, and 150,000 respectively) that vest 100% on January 1, 2024, contingent upon achieving a pre-determined financial objective related to the Company's available cash.
- Risks: The shift in the CEO's bonus metric to a cash-related objective suggests management is prioritizing liquidity preservation. The filing does not explicitly list other risks or contingencies beyond the standard terms of the equity plans.
Investor Verification Checklist
- Verify the specific "pre-determined financial objective" related to available cash required for the January 2024 RSU vesting.
- Confirm the current cash position of Oncocyte Corporation to assess the feasibility of the new cash-related bonus targets.
- Review the total dilution impact of the 100,000 options and 650,000 RSUs granted to the three executives.
- Check subsequent filings for the actual achievement of the modified CEO bonus objectives for fiscal 2022.